| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8245842 | International Journal of Radiation Oncology*Biology*Physics | 2006 | 8 Pages |
Abstract
Conclusion: Toxicity is acceptable at the current doses of erlotinib plus RT. The study was modified to include concurrent and adjuvant temozolomide, and accrual is in progress.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Sunil M.D., Paul D. M.D., Karla V. Ph.D., John B. M.D., Joon H. M.D., Caterina M.D., Kurt A. M.D., Francois J. M.D., L. Burt M.D., Jan C. M.D.,